Literature DB >> 34247197

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Tomas Jelinek1, Tereza Sevcikova2, David Zihala2, Tereza Popkova2, Veronika Kapustova2,3, Lucie Broskevicova2, Lenka Capkova4, Lucie Rihova5, Renata Bezdekova5, Sabina Sevcikova6, Vladimir Zidlik7, Martin Havel8, Hana Plonkova2, Alexandra Jungova9, Jiri Minarik10, Martin Stork11, Ludek Pour11, Petr Pavlicek12, Ivan Spicka13, Vladimir Maisnar14, Jakub Radocha14, Michal Simicek2, Roman Hajek2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34247197     DOI: 10.1038/s41375-021-01343-w

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

Review 1.  Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.

Authors:  Abdullah Al Emran; Aniruddha Chatterjee; Euan J Rodger; Jessamy C Tiffen; Stuart J Gallagher; Michael R Eccles; Peter Hersey
Journal:  Trends Immunol       Date:  2019-03-07       Impact factor: 16.687

Review 2.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

Review 3.  Multiple myeloma.

Authors:  Niels W C J van de Donk; Charlotte Pawlyn; Kwee L Yong
Journal:  Lancet       Date:  2021-01-30       Impact factor: 79.321

4.  CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

Authors:  Inger S Nijhof; Tineke Casneuf; Jeroen van Velzen; Berris van Kessel; Amy E Axel; Khaja Syed; Richard W J Groen; Mark van Duin; Pieter Sonneveld; Monique C Minnema; Sonja Zweegman; Christopher Chiu; Andries C Bloem; Tuna Mutis; Henk M Lokhorst; A Kate Sasser; Niels W C J van de Donk
Journal:  Blood       Date:  2016-06-15       Impact factor: 22.113

Review 5.  Extramedullary disease in multiple myeloma - controversies and future directions.

Authors:  Sabina Sevcikova; Jiri Minarik; Martin Stork; Tomas Jelinek; Ludek Pour; Roman Hajek
Journal:  Blood Rev       Date:  2019-04-13       Impact factor: 8.250

Review 6.  Monoclonal antibodies - A new era in the treatment of multiple myeloma.

Authors:  Tomas Jelinek; Roman Hajek
Journal:  Blood Rev       Date:  2015-08-24       Impact factor: 8.250

7.  Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.

Authors:  Ludek Pour; Sabina Sevcikova; Henrieta Greslikova; Renata Kupska; Petra Majkova; Lenka Zahradova; Viera Sandecka; Zdenek Adam; Marta Krejci; Petr Kuglik; Roman Hajek
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

8.  DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.

Authors:  Priya Choudhry; Margarette C Mariano; Huimin Geng; Thomas G Martin; Jeffrey L Wolf; Sandy W Wong; Nina Shah; Arun P Wiita
Journal:  Leukemia       Date:  2019-10-08       Impact factor: 11.528

9.  Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Evangelos Terpos; María-Victoria Mateos; Sonja Zweegman; Gordon Cook; Michel Delforge; Roman Hájek; Fredrik Schjesvold; Michele Cavo; Hartmut Goldschmidt; Thierry Facon; Hermann Einsele; Mario Boccadoro; Jesús San-Miguel; Pieter Sonneveld; Ulrich Mey
Journal:  Hemasphere       Date:  2021-02-03

10.  Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT.

Authors:  Nico Gagelmann; Diderik-Jan Eikema; Simona Iacobelli; Linda Koster; Hareth Nahi; Anne-Marie Stoppa; Tamás Masszi; Denis Caillot; Stig Lenhoff; Miklos Udvardy; Charles Crawley; William Arcese; Clara Mariette; Ann Hunter; Xavier Leleu; Martin Schipperus; Michel Delforge; Pietro Pioltelli; John A Snowden; Maija Itälä-Remes; Maurizio Musso; Anja van Biezen; Laurent Garderet; Nicolaus Kröger
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

View more
  3 in total

Review 1.  Advances in the treatment of extramedullary disease in multiple myeloma.

Authors:  Yating Li; Zhengxu Sun; Xiaoyan Qu
Journal:  Transl Oncol       Date:  2022-06-06       Impact factor: 4.803

Review 2.  Natural Killer Cells in the Malignant Niche of Multiple Myeloma.

Authors:  Ondrej Venglar; Julio Rodriguez Bago; Benjamin Motais; Roman Hajek; Tomas Jelinek
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

3.  Identification of patients at high risk of secondary extramedullary multiple myeloma development.

Authors:  Martin Stork; Sabina Sevcikova; Jiri Minarik; Petra Krhovska; Jakub Radocha; Lenka Pospisilova; Lucie Brozova; Jiri Jarkovsky; Ivan Spicka; Jan Straub; Petr Pavlicek; Alexandra Jungova; Tomas Jelinek; Viera Sandecka; Vladimir Maisnar; Roman Hajek; Ludek Pour
Journal:  Br J Haematol       Date:  2021-11-02       Impact factor: 8.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.